Merck acquires OncoEthix, gains OTX015

Subscribe via: RSS

Big pharma, M&A, Pharma

Merck acquires OncoEthix, gains OTX015

Posted on 18 December 2014

Merck has acquired OncoEthix.

Through the acquisition, Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

Financial terms of the acquisition include an upfront payment of up to $110 million to OncoEthix.

Additional milestone payments of up to $265 million are contingent upon certain clinical and regulatory events being achieved.

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog